Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NamePresident's Cancer PanelAgency NameDepartment of Health and Human Services
Fiscal Year2018Committee Number1001
Original Establishment Date11/20/1985Committee StatusChartered
Actual Termination Date Committee URLhttps://prescancerpanel.cancer.gov/
New Committee This FYNoPresidential Appointments*Yes
Terminated This FYNoMax Number of Members*3
Current Charter Date5/31/2018Designated Fed Officer Position Title*SPECIAL ASSISTANT TO THE DIRECTOR, RARE TUMORS INITIATIVE
Date Of Renewal Charter5/31/2020Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*ABBY
Exempt From Renewal*NoDesignated Federal Officer Middle NameB.
Specific Termination AuthorityDesignated Federal Officer Last Name*SANDLER
Establishment Authority*Statutory (Congress Created)Designated Federal Officer SuffixPHD
Specific Establishment Authority*42 U.S.C. 285a-4Designated Federal Officer Phone*240-781-3387
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*240-541-4521
Committee Type*ContinuingDesignated Federal Officer Email*sandlera@mail.nih.gov
Presidential*Yes
Committee Function*National Policy Issue Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The committee is composed of three members who provide advice and recommendations to the President of the United States in the areas of policy, health care, research, and information dissemination. The current President's Cancer Panel (PCP, the Panel) member is Dr. Barbara K. Rimer (Chair), who was appointed by President Obama in late 2011 and reappointed by President Obama in 2015. The Panel monitors the development and execution of the activities of the National Cancer Program. Any delays or blockages in rapid execution of the Program are immediately brought to the attention of the President. The Panel conducts meetings throughout the country that serve as a forum for the scientific community and for the public. Based on expert testimony presented and discussions occurring at these meetings, the Panel makes recommendations, some of which have affected the initiation of new NCI programs and the implementation of existing priorities. In 2018, the Panel completed its work on the 2016-2017 workshop series entitled “Ensuring Patients’ Access to High-Value Cancer Drugs”, with their release of the report, “Promoting Value, Affordability, and Innovation in Cancer Drug Treatment” in March. The report recommends critical actions to ensure affordable access to high-value cancer drugs.
How is membership balanced?*The President's Cancer Panel consists of three persons appointed by the President, who by virtue of their training, experience and background, are exceptionally qualified to appraise the National Cancer Program. It is mandated that at least two of the members of the Panel will be distinguished scientists or physicians.
How frequent & relevant are cmte mtgs?*Meetings are generally held not less than four times each fiscal year at the call of the Chair. The Panel did not meet in FY18 because of an inability to establish the quorum necessary to hold a meeting.
Why advice can't be obtained elsewhere?*The President's Cancer Panel was established by law, and the chairman submits to the President, the Secretary, and the Congress an annual evaluation of the National Cancer Program and suggestions for improvements. The Panel also submits such other reports as the White House requests. The quality, scope, and balance of advice from this Panel cannot be obtained from NIH staff or from other established sources because the membership of the Panel is constituted to meet the specific requirements of its mandated mission to appraise the National Cancer Program.
Why close or partially close meetings?N/A
Recommendation RemarksMembers: The terms for Dr. Rimer and Mr. Harper changed due to administrative extensions. Mr. Harper’s term ended on 3/16/18. As such, their term of service end date is different than what was reported on the FY17 ACR.

Meetings: No meetings were held during FY18 due to the inability to establish the quorum necessary to hold a meeting.

Costs: The reduction in FY18 operating costs was due to no meetings being held during the fiscal year.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesYesAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryYesAction OtherNo
Outcome Increased Customer SatisfactionYesAction CommentN/A
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentThe PCP, because it is charged under the Cancer Act to assess the program, has indicated that it has responsibilities in all areas of the cancer program which includes the above.Number Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentNIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.Grants Review CommentN/A
Number Of Recommendations*192Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThere were 6 recommendations made in FY18 through a report that was finalized and released in FY18.Access Agency WebsiteYes
% of Recs Fully Implemented*0.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentDue to the large breadth and complexity of the recommendations made by this committee, NCI staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*0.00%Access PublicationsYes
% of Recs Partially Implemented CommentDue to the large breadth and complexity of the recommendations made by this committee, NCI staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.Access OtherYes
Agency Feedback*NoAccess CommentInformation on the PCP can be found at the President’s Cancer Panel website at https://prescancerpanel.cancer.gov. Findings are also communicated through mailings and in person briefings.
Agency Feedback CommentN/ANarrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold, resulting in better health for everyone. Annual identification and assessment of the issues facing the National Cancer Program contribute to the advancement of this mission and the development of the NIH strategic plan in regards to cancer. Over its approximately 40 year history, the Panel has engaged in active dialogue with all participants in the National Cancer Program [the Program] in an effort to assess the progress and coordination of the Program. The Panel has generally held four or more meetings in each series to gather information and to stimulate discussion among prominent scientists, clinicians, academia, business, industry and the government. Recent topics have included how to increase the uptake of the human papillomavirus (HPV) vaccine; the potential for connected health strategies and technologies to engage and activate individuals and patients, with the ultimate goal of improving cancer-related outcomes; and ensuring patients' access to high-value cancer drugs. As a link between the President and the public on cancer issues, the Panel provides information that informs cancer policy at the Executive level through its mandate to assess the efficacy of the National Cancer Program. The meetings of the Panel present a unique opportunity to identify and bring together the vast research, health care and manpower resources of this Nation by eliciting public testimony in assessment of the National Cancer Program. The PCP meetings provide the President with the means to identify both the strengths and the weaknesses of the National Cancer Program and the opportunity to seek out needed adjustments. The Panel fills a critical need as the sometimes costly screening, treatment, and technological advances made possible through cancer research must be successfully and equitably applied throughout the country to alleviate suffering and death caused by cancer. During the 2016-2017 workshop series entitled “Ensuring Patients’ Access to High-Value Cancer Drugs”, the Panel explored a variety of factors that influence drug costs and pricing, such as research and development costs, payment models, reimbursement policies and regulations, organizational treatment guidelines, and other market forces. The Panel's final report on this series, “Promoting Value, Affordability, and Innovation in Cancer Drug Treatment" was released in March 2018.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$1,878.00Est Payments to Non-Fed Members Next FY*$24,648.00
Payments to Federal Members* Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$228,885.00Estimated Payments to Federal Staff*$233,234.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$357.00Est Travel Reimb Non-Fed Members nextFY*$11,847.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$4,642.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$229,232.00Est. Other Costs Next FY*$523,562.00
Total Costs$460,352.00Est. Total Next FY*$797,933.00
Federal Staff Support (FTE)*1.50Est. Fed Staff Support Next FY*1.50
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

  
ActionCommittee System IDCommittee NameFiscal Year
 COM-002028President's Cancer Panel2017
 COM-002225President's Cancer Panel2016
 COM-003838President's Cancer Panel2015
 COM-004410President's Cancer Panel2014
 COM-006269President's Cancer Panel2013
 COM-006548President's Cancer Panel2012
 COM-008226President's Cancer Panel2011
 COM-008779President's Cancer Panel2010
 COM-010367President's Cancer Panel2009
 COM-010746President's Cancer Panel2008
 COM-012263President's Cancer Panel2007
 COM-012504President's Cancer Panel2006
 COM-013756President's Cancer Panel2005
 COM-014416President's Cancer Panel2004
 COM-015700President's Cancer Panel2003
 COM-016768President's Cancer Panel2002
 COM-017897President's Cancer Panel2001
 COM-018492President's Cancer Panel2000
 COM-019822President's Cancer Panel1999
 COM-020610President's Cancer Panel1998
 COM-021459President's Cancer Panel1997